Amgen (AMGN) 10-K Summaries & Annual Filing History
Review Amgen Inc. (AMGN) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Amgen discovers, develops, manufactures, and delivers innovative medicines for serious diseases. For the fiscal year covered, revenue grew, operating income and net income were reported, and operating cash flow was generated.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$36.8B
Revenue reported for the fiscal year.
Operating income
$9.1B
Income from operations reported for the year.
Net income
$7.7B
Net income reported for the year.
Operating cash flow
$10B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $26.3B | +1.3% |
| Dec 31, 2023 | $28.2B | +7.1% |
| Dec 31, 2024 | $33.4B | +18.6% |
| Dec 31, 2025 | $36.8B | +10.0% |
Business overview
Amgen is a biotechnology company that discovers, develops, manufactures, and delivers medicines for areas of high unmet medical need. Its principal products include Prolia, Repatha, Otezla, ENBREL, and several others. The company also markets additional products such as MVASI, PAVBLU, and UPLIZNA.
Financial performance
Revenue increased compared to the prior year. Operating income and net income were both reported for the period. Operating cash flow was also generated during the fiscal year.
Material risks
The filing includes a section on risk factors, but no specific risks are detailed in the supplied context. Readers should refer to the full risk factors section in the filing for material risks.
Liquidity and capital
The filing mentions liquidity and capital resources, trends, planned dividends, stock repurchases, and collaborations, but no specific capital allocation actions are detailed in the supplied context.
What to watch
Monitor any updates to the risk factors section in the next filing for changes in material risks.